Health ❯ Healthcare ❯ Pharmaceuticals ❯ Clinical Trials

Obesity Treatment

Wave Life Sciences Soars on Obesity Trial Signal as It Begins $250 Million Stock Offering

The INHBE-targeting siRNA produced durable Activin E suppression supporting infrequent dosing.

Lilly’s Oral GLP-1 Orforglipron Beats Farxiga and Placebo in Two Phase 3 Diabetes Trials